14 Results for "

hepatic glycogen

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "hepatic glycogen" in MCE Product Catalog:

Cat. No.: HY-Y1212
CAS No.: 61790-53-2
Synonyms: Diatomaceous earth
Celite (Diatomaceous earth) is a filter aid. Celite induces hepatic tryptophan oxygenase activity and reduces hepatic glycogen in mouse experiments. Celite can be used for studies of endotoxemia .
loading...
    loading...
Cat. No.: HY-42680
CAS No.: 87-81-0
Synonyms: D-(-)-Tagatose
D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-108615
CAS No.: 186392-43-8
Purity:  98.58%
Synonyms: GPi 819
CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P4060
CAS No.: 59763-91-6
Research Areas:  

Metabolic Disease Endocrinology

Pancreatic polypeptide is a peptide secreted by the endocrine PP cells of the pancreas that regulates pancreatic secretory activity and also affects hepatic glycogen stores and gastrointestinal secretion .
loading...
    loading...
Cat. No.: HY-177297
CAS No.: 1067877-83-1
Synonyms: NVP-LCZ960
Target:  

Glucokinase

Research Areas:  

Metabolic Disease

LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-Y1150
CAS No.: 75-98-9
Synonyms: Trimethylmethanecarboxylic acid; Versatic 5 acid; tert-Pentanoic acid
Target:  

Antibiotic

Research Areas:  

Inflammation/Immunology

Pivalic acid (Trimethylmethanecarboxylic acid) is a carboxylic acid. Pivalic acid induces Carnitine deficiency. Pivalic acid conjugated with Antibiotics, such as Pivmecillinam (HY-B0810) and Pivampicillin (HY-119011), are used in urinary tract infection. Pivalic acid can be used in physical exercise research .
loading...
    loading...
Cat. No.: HY-139140
CAS No.: 100276-03-7
Target:  

Phosphorylase

Research Areas:  

Metabolic Disease

BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-42680S
CAS No.: 478506-42-2
Synonyms: D-(-)-Tagatose-13C
D-Tagatose- 13C is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
loading...
    loading...
Cat. No.: HY-42680R
CAS No.: 87-81-0
Synonyms: D-(-)-Tagatose (Standard)
D-Tagatose (Standard) is the analytical standard of D-Tagatose (HY-42680). This product is intended for research and analytical applications. D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
loading...
    loading...
Cat. No.: HY-42680S1
CAS No.: 478506-44-4
Synonyms: D-(-)-Tagatose-13C-1
D-Tagatose- 13C-1 is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
loading...
    loading...
Cat. No.: HY-P2437
CAS No.: 91921-56-1
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Insulin B (20-30) is the C-terminal undecapeptide fragment of the Insulin B chain. Insulin stimulates tissue glucose uptake, inhibits fatty acid release from adipose tissue, suppresses hepatic ketogenesis, and promotes the deposition of fat and glycogen .
loading...
    loading...
Cat. No.: HY-108615R
CAS No.: 186392-43-8
Synonyms: GPi 819 (Standard)
CP-316819 (GPi 819) Standard is the analytical standard of CP-316819 (HY-108615). This product is intended for research and analytical applications. CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes.
loading...
    loading...
Cat. No.: HY-183456
CAS No.: 71308-35-5
Tyrphostin AG17 is an orally active CDK2 inhibitor and EGFR tyrosine kinase antagonist. Tyrphostin AG17 reduces the levels of p21 and p16. Tyrphostin AG17 induces G1 phase cell cycle arrest, Apoptosis, mitochondrial dysfunction, decreased ATP levels, and inhibits DNA, RNA and protein synthesis, adipogenesis, and lipid synthesis. Tyrphostin AG17 inhibits fat accumulation, white adipose tissue hypertrophy, and alterations of glycogen and lipid inclusions in hepatocytes in obese mice without changing their serum biochemical parameters. Tyrphostin AG17 exhibits anticancer effects. Tyrphostin AG17 can be used in research related to immunoblastic lymphoma, leukemia, ovarian cancer, glioblastoma, colon cancer, breast cancer, melanoma, obesity and hepatic steatosis .
loading...
    loading...
Cat. No.: HY-N20714
CAS No.: 197449-09-5
(2R,3R,4R)-2-Methylpiperidine-3,4-diol is a six-membered ring iminosugar analog. Fagomine (HY-13005), an analog of (2R,3R,4R)-2-hydroxymethylpiperidine-3,4-diol, exhibits weak inhibitory activity against hepatic glycogen phosphorylase, while its isomer Isofagomine (HY-14829) possesses potent inhibitory activity. (2R,3R,4R)-2-Methylpiperidine-3,4-diol can be used in studies related to type 2 diabetes .
loading...
    loading...
  • 1